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Purpose of the study
The objective of our study was to assess the association
between HIV-RNA viral load (HIV-VL) and metabolic syn-
drome (MS) prevalence in a cohort of HIV patients expe-
rienced to ART with lipodystrophy (LD).
Methods
This was a cross-sectional observational study that
included all consecutive HIV-infected patients evaluated
at the metabolic clinic of the University of Modena and
Reggio Emilia, Italy, between January 2006 and January
2008 who had received antiretroviral therapy for at least 2
years. Lipodystrophy and metabolic syndrome were
defined according to MACS classification and to NCEP-
ATP III criteria, respectively.
Summary of results
1,348 patients were analyzed. 850 (63.1%) were males;
mean age was 44.8 years (± 7.1). Obesity, defined by body
mass index >30, was diagnosed in 78 patients (5.8%).
Prevalence of metabolic syndrome was 24.4%. 84.8% of
the patients had HIV VL<400 copies/mL. LD was diag-
nosed in 88.3%: 515 (39.3%) patients had lipoatrophy;
116 (8.9%) had fat accumulation; and 527 (40.2%) had
mixed forms. Patients with MS had statistically significant
greater value of each diagnostic criteria than those without
(Table 1). Higher BMI, lipodystrophy presence, as well as
VAT/TAT, trunk fat, total fat and total lean mass were asso-
ciated with MS diagnosis (Table 1). MS was more preva-
lent in patients with higher log HIV-VL, PI and NNRTI
current use and NNRTI exposure (Table 1). Multivariate
logistic regression shown in Table 2 illustrates that log
HIV-VL is an independent predictor of metabolic syn-
drome.
Conclusion
Our study highlights that HIV-infected patients experienc-
ing virological failure are more at risk to develop MS. It is
necessary to obtain virologic suppression to prevent not
only AIDS-related opportunistic infections, but also those
cardiovascular events and diabetes related to MS presence.
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Table 1: 
SM+ SM- p
Systolic BP, mmHg 129.84 ± 14.43 117.72 ± 14.67 < 0.0001
Diastolic BP, mmHg 86.88 ± 11.01 76.43 ± 12.42 < 0.0001
Glucose, mg/dL 107.73 ± 34.57 91.74 ± 13.84 < 0.0001
HDL, mg/dL 35.85 ± 8.63 48.84 ± 16.08 < 0.0001
Triglycerides, mg/dL 300.91 ± 206.15 179.15 ± 159.54 < 0.0001
Apo B, mg/dL 111.51 ± 29.64 100.57 ± 31.22 < 0.0001
TCol/HDL 5.58 ± 1.63 4.21 ± 1.46 < 0.0001
HOMA > 3.8, n (%) 210 (65.02) 354 (35.36) < 0.0001
HOMA, median (IQR) 5.14 (3.00; 8.15) 2.95 (1.93; 4.57) < 0.0001
HIV duration, months 169.33 ± 62.15 172.35 ± 64.46 0.46
Log10 VL 2.17 ± 0.94 2.02 ± 0.79 0.0048
CD4 nadir, median (IQR) 150 (50; 250) 146 (60; 238) 0.86
CD4 current, median (IQR) 500 (342; 701) 502 (357; 681) 0.99
BMI 25.17 ± 4.40 22.80 ± 3.38 < 0.0001
Waist, cm 91.04 ± 11.27 83.71 ± 9.41 < 0.0001
PI current 199 (61.61) 529 (52.85) 0.006
NRTI current 321 (99.38) 998 (98.70) 0.31
NNRTI current 90 (27.86) 381 (38.06) 0.001
PI exposure, months 51.37 ± 47.95 49.05 ± 43.57 0.41
NRTI exposure, months 104.08 ± 58.67 108.46 ± 56.17 0.23
NNRTI exposure, months 26.15 ± 26.78 30.18 ± 30.94 0.0358
HCV 102 (31.58) 372 (37.16) 0.17
VAT/TAT 0.54 ± 0.17 0.48 ± 0.18 < 0.0001
%fat leg, median (IQR) 8.97 (5.89; 15.79) 9.67 (5.86; 15.88) 0.61
%fat leg/BMI, median (IQR) 0.36 (0.25; 0.61) 0.41 (0.26; 0.70) 0.0074
Trunk fat, g 7343.25 ± 3720.89 5943.93 ± 3219.04 < 0.0001
Total fat, g 12451.16 ± 7293.54 10200.50 ± 5768.74 < 0.0001
Total lean, g 53038.16 ± 9722.90 48689.95 ± 10030.84 < 0.0001
Table 2: 
Variables Adjusted OR (95% CI) P-value
Log10 VL 1.23 (1.01–1.65) 0.006
Age (per 10-year increment) 1.41 (1.18–1.69) < 0.0001
Waist, cm 1.05 (1.03–1.06) < 0.0001
HOMA > 3.8 2.49 (1.89–3.29) < 0.0001
